NO20070195L - Vaksine mot HPV16 og HPV18 og minst en annen HPV-type valgt fra HPV31, 45 eller 52 - Google Patents

Vaksine mot HPV16 og HPV18 og minst en annen HPV-type valgt fra HPV31, 45 eller 52

Info

Publication number
NO20070195L
NO20070195L NO20070195A NO20070195A NO20070195L NO 20070195 L NO20070195 L NO 20070195L NO 20070195 A NO20070195 A NO 20070195A NO 20070195 A NO20070195 A NO 20070195A NO 20070195 L NO20070195 L NO 20070195L
Authority
NO
Norway
Prior art keywords
hpv31
hpv18
type selected
vaccine against
hpv type
Prior art date
Application number
NO20070195A
Other languages
English (en)
Norwegian (no)
Inventor
Martine Anne Cecil Wettendorff
Jean Stephenne
Serge Debrus
Marie-Therese Martin
Robert John Stephen
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0413510.9A external-priority patent/GB0413510D0/en
Priority claimed from US11/114,301 external-priority patent/US20050287161A1/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20070195L publication Critical patent/NO20070195L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20070195A 2004-06-16 2007-01-11 Vaksine mot HPV16 og HPV18 og minst en annen HPV-type valgt fra HPV31, 45 eller 52 NO20070195L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0413510.9A GB0413510D0 (en) 2004-06-16 2004-06-16 Vaccine
US11/114,301 US20050287161A1 (en) 2002-12-20 2005-04-26 Vaccine
PCT/EP2005/006461 WO2005123125A1 (en) 2004-06-16 2005-06-14 Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52

Publications (1)

Publication Number Publication Date
NO20070195L true NO20070195L (no) 2007-01-15

Family

ID=35160037

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070195A NO20070195L (no) 2004-06-16 2007-01-11 Vaksine mot HPV16 og HPV18 og minst en annen HPV-type valgt fra HPV31, 45 eller 52

Country Status (18)

Country Link
EP (1) EP1758609B1 (enExample)
JP (1) JP2008502633A (enExample)
KR (1) KR20070029254A (enExample)
AR (1) AR049354A1 (enExample)
AU (1) AU2005253723B2 (enExample)
BR (1) BRPI0512042B8 (enExample)
CA (1) CA2566620C (enExample)
FR (2) FR15C0082I2 (enExample)
IL (1) IL179138A0 (enExample)
LU (3) LU92899I2 (enExample)
MA (1) MA28692B1 (enExample)
MX (1) MXPA06014515A (enExample)
NO (1) NO20070195L (enExample)
PE (1) PE20060434A1 (enExample)
PL (1) PL1758609T3 (enExample)
RU (1) RU2420313C2 (enExample)
SG (1) SG153837A1 (enExample)
WO (1) WO2005123125A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007013475A (es) * 2005-04-26 2008-04-02 Glaxosmithkline Biolog Sa Vacuna.
ES2519490T3 (es) * 2008-07-31 2014-11-07 Glaxosmithkline Biologicals S.A. Vacuna contra HPV
US9566323B2 (en) * 2009-06-19 2017-02-14 Eyegene Inc. Vaccine for cervical cancer
CN103119168A (zh) * 2010-07-15 2013-05-22 不列颠哥伦比亚癌症局分支机构 人乳头瘤病毒e7抗原组合物及其用途
EP3269388A1 (en) 2012-10-30 2018-01-17 Pfizer Inc. Recombinant particle based vaccines against human cytomegalovirus infection
CA2965498A1 (en) * 2014-10-24 2016-04-28 Hpvvax, Llc. Compositions and uses of a papilloma virus (hpv) vaccine for the treatment of hpv related cancer and skin lesions
CN107188966B (zh) 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
PT1572233E (pt) * 2002-12-20 2011-06-07 Glaxosmithkline Biolog Sa Utilização de hpv16 e hpv18 como vacina contra um ou mais de tipos de hpv oncogénicos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

Also Published As

Publication number Publication date
RU2006143804A (ru) 2008-08-20
LU92899I2 (fr) 2016-03-08
AR049354A1 (es) 2006-07-19
CA2566620A1 (en) 2005-12-29
WO2005123125A1 (en) 2005-12-29
CA2566620C (en) 2014-03-11
MXPA06014515A (es) 2007-03-23
FR15C0082I2 (fr) 2016-10-28
EP1758609A1 (en) 2007-03-07
AU2005253723B2 (en) 2011-01-20
LU92900I2 (fr) 2016-03-08
BRPI0512042A (pt) 2008-02-06
PE20060434A1 (es) 2006-06-08
AU2005253723A1 (en) 2005-12-29
KR20070029254A (ko) 2007-03-13
JP2008502633A (ja) 2008-01-31
BRPI0512042B1 (pt) 2019-01-22
LU92898I2 (fr) 2016-03-08
RU2420313C2 (ru) 2011-06-10
IL179138A0 (en) 2007-03-08
FR15C0082I1 (fr) 2016-01-08
EP1758609B1 (en) 2012-10-03
PL1758609T3 (pl) 2013-02-28
FR15C0084I1 (enExample) 2016-01-08
SG153837A1 (en) 2009-07-29
FR15C0084I2 (fr) 2016-10-28
MA28692B1 (fr) 2007-06-01
BRPI0512042B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
EP4215543A3 (en) Hpv-specific binding molecules
CY1111552T1 (el) Χρηση hpv16 και hpv18 ως εμβολιο εναντι ενος ή περισσοτερων ογκογονικου hpv τυπου 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
Xu et al. Prophylactic vaccination against human papillomaviruses to prevent vulval and vaginal cancer and their precursors
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
CA2370372A1 (en) Porcine reproductive and respiratory syndrome vaccine, based on isolate ja-142
Medina et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls
AR039005A1 (es) Antigenos virales
ATE499113T1 (de) Influenzavirus-impfstoffzusammensetzung
CY1113830T1 (el) Εμβολιο εναντι hpv16 και hpv18 και τουλαχιστον ενος αλλου τυπου hpv ο οποιος επιλεγεται απο hpv 31,45 ή 52
EP2065392A3 (en) Fusion antigen uses as vaccine
Szarewski HPV vaccination and cervical cancer
WO2009042895A3 (en) Reagents for inducing an immune response
Seitz et al. A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses
EP2589604A4 (en) SHORTEN L1 PROTEIN OF THE TYPE 52 HUMAN PAPILLOMA VIRUS
Wang et al. Immunoprevention of human papillomavirus–associated malignancies
JOP20220187A1 (ar) لقاح فيروس الورم الحليمي البشري (hpv)
ES533111A0 (es) Un metodo de preparar una vacuna viva
JP2006512413A5 (enExample)
Franceschi et al. Human papillomavirus vaccines and anal carcinoma
ATE506063T1 (de) Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien
SG153837A1 (en) Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
MY207280A (en) Polyvalent immunogenicity composition for human papillomavirus
MXPA02003328A (es) Vacuna.
DE60236806D1 (de) Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln
Afshani et al. Immunogenicity and safety of a bivalent, adjuvant system 04–adjuvanted human papillomavirus vaccine in healthy female volunteers aged 15–25: a randomized, double-blind, phase III, noninferiority clinical trial

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application